BioTek Readers Receive BellBrook Certifications
News Sep 11, 2015
BioTek's complete line of multi-mode microplate readers have now earned Transcreener HTS Assay certifications from BellBrook Labs. Performance of BioTek readers including the Synergy™ Neo2 and Cytation™ 5 have been confirmed as meeting validation requirements across BellBrook's supported Fluorescence Intensity, Fluorescence Polarization and TR-FRET detection modes.
Synergy Neo2 is designed for speed and ultra high performance, incorporating BioTek's patented Hybrid Technology™, with its independent optical paths that ensure uncompromised performance in all detection modes. Continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to 4 PMTs provide ultra-fast measurements with excellent results.
Cytation 5 is a modular, upgradable multi-mode reader that combines automated digital microscopy and conventional microplate detection. Cytation 5 also incorporates BioTek’s patented Hybrid Technology with both filter- and monochromator-based detection; the microscopy module provides up to 60x magnification in fluorescence, brightfield, color brightfield and phase contrast.
Available laser autofocus and image-based autofocus ensures fast and accurate image acquisition with minimized phototoxicity across a broad application range.
Other BioTek readers earning the Transcreener certifications include Synergy™ H1, Synergy™ 2, and Synergy™ HTX.
How To Build A Better Railway - In (Almost) Every Cell In Your BodyNews
New research from the University of Warwick shows how a microscopic ‘railway’ system in our cells can optimise its structure to better suit bodies’ needs.READ MORE
‘Digistain’ Technology Offers Revolution in Detailed Cancer DiagnosisNews
New cutting edge technology can be used to grade cancer tumours, eradicating human subjectivity and ensuring patients get the right treatment.READ MORE
Understanding 'Disease Mechanisms' of ALSNews
Researchers are making strides in understanding the disease mechanism of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. They recently found that ubiquitin eliminates droplets of Ubiquilin-2 (UBQLN2) in solution. The discovery is noteworthy because UBQLN2 is a protein-encoding gene, mutations to which cause ALS and various types of dementia.READ MORE